DRMA|EPS -$8.16|Net Loss $7.5MDermata Therapeutics recently pivoted from pharmaceutical development to direct-to-consumer skincare. They expect to launch their new Tome skincare brand in mid-2026.
Revenue is not reported in the operating statements. Net loss per common share (EPS) was $(8.16) in 2025, improving significantly from $(80.32) in 2024. The total net loss for the year was $7.56 million.
Cash and cash equivalents reached $7.5 million by year-end 2025, an increase from $3.2 million in 2024. Supported by $12.1 million in net financing proceeds, these funds are expected to sustain the company’s operations into early 2027.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.